Skip to content

Harmony Biosciences Holdings, Inc. HRMY Additional Paid-In Capital

Additional Paid-In Capital at other companies

Acadia Pharmaceuticals logo
Acadia PharmaceuticalsACAD
$3.06B+3.7%
Xenon Pharmaceuticals logo
Xenon PharmaceuticalsXENE
$264.88M+27.1%
Jazz Pharmaceuticals logo
Jazz PharmaceuticalsJAZZ
Alkermes logo
AlkermesALKS
Axsome Therapeutics logo
Axsome TherapeuticsAXSM
Neurocrine Biosciences logo
Neurocrine BiosciencesNBIX

Other financials

Income statement

See full
Revenue$215.4M+16.6%
Gross profit$170.9M+11.9%
Operating income$37.3M-33.7%
Net income$32.5M-28.7%
EPS (diluted)$0.55-29.5%

Balance sheet

See full
Cash & equivalents$589.4M+20.5%
Total debt$164.6M-7.2%
Total equity$910.3M+26.3%
Total assets$1.3B+20.5%

Cash flow

See full
Operating cash flow$27.8M-18.3%
CapEx$107.0K-79.1%
Free cash flow$126.0M+67.9%

Valuation

See full
Market cap$1.99B-14.9%

Profitability

See full
Gross margin76.5%-1.8pp
Operating margin21.1%-5.1pp
Net margin16.2%-4.3pp
FCF margin40.1%+9.5pp

Returns & leverage

See full
Return on equity17.9%-6.9pp
Debt / equity0.2×-0.1×
Current ratio3.6×-0.1×

Where this comes from

Reported directly by Harmony Biosciences Holdings, Inc. in its filing.

Tagged under the XBRL concept us-gaap:AdditionalPaidInCapitalCommonStock.

The official record: Harmony Biosciences Holdings, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Harmony Biosciences Holdings, Inc.'s additional paid-in capital.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Harmony Biosciences Holdings, Inc.'s additional paid-in capital?
Harmony Biosciences Holdings, Inc. (HRMY) reported additional paid-in capital of $717.37M in Q1 2026.
How has Harmony Biosciences Holdings, Inc.'s additional paid-in capital changed year-over-year?
Harmony Biosciences Holdings, Inc.'s additional paid-in capital increased by 6.7% year-over-year, from $672.5M to $717.37M.
What is the long-term trend for Harmony Biosciences Holdings, Inc.'s additional paid-in capital?
Over 5 years (2020 to 2025), Harmony Biosciences Holdings, Inc.'s additional paid-in capital has grown at a 3.9% compound annual growth rate (CAGR), from $585.37M to $708.97M.
What does additional paid-in capital mean?
This represents the excess amount paid by investors for common shares over their par value. It is a key component of shareholders' equity that captures the capital raised through equity offerings beyond the nominal value of the stock. It reflects the historical market premium at which the company has issued its shares.